Crenigacestat is primarily used in cancer research, particularly as a gamma-secretase inhibitor. It is investigated for its ability to block the Notch signaling pathway, which plays a key role in the development and progression of certain tumors. By inhibiting this pathway, Crenigacestat may help suppress tumor growth in cancers such as T-cell acute lymphoblastic leukemia and other Notch-dependent malignancies. It has also been studied in combination with other anticancer agents to enhance therapeutic efficacy. Additionally, research explores its potential in solid tumors including breast, lung, and pancreatic cancers. Its application remains largely experimental and confined to clinical trials and preclinical studies.